Bitte beachten Sie: Suchbegriffe unter einer Länge von 3 Buchstaben werden ignoriert.
268 Treffer:
41.
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligibl
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-03
42.
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-03
43.
A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 fol
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-03
44.
Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induc
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-03
45.
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-04-03
46.
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalido
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-04-03
47.
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-04-03
48.
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-03
49.
CAPTOR-BC: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-03
50.
Comprehensive assessment of clinical features and biomarkers to identify patients with advanced or metastatic breast cancer for marker driven trials in humans (CATCH).
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-03